Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies-Reference-Cited by-同舟云学术

Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies

Published:2021-10 Issue: Volume:222 Page:113584
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Vuong Wayne^ORCID,Fischer Conrad,Khan Muhammad Bashir,van Belkum Marco J.,Lamer Tess^ORCID,Willoughby Kurtis D.,Lu Jimmy^ORCID,Arutyunova Elena,Joyce Michael A.^ORCID,Saffran Holly A.,Shields Justin A.^ORCID,Young Howard S.^ORCID,Nieman James A.^ORCID,Tyrrell D. Lorne^ORCID,Lemieux M. Joanne,Vederas John C.^ORCID

Funder

Canadian Institutes of Health Research

Natural Sciences and Engineering Research Council of Canada

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference38 articles.

1. The genetic sequence, origin, and diagnosis of SARS-CoV-2;Wang;Eur. J. Clin. Microbiol. Infect. Dis.,2020

2. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors;Zhang;Science,2020

3. A contemporary view of coronavirus transcription | J. Virol., (n.d.). https://jvi.asm.org/content/81/1/20 (accessed February 6, 2021).

4. An overview of severe acute respiratory syndrome–coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy;Pillaiyar;J. Med. Chem.,2016

5. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication;Vuong;Nat. Commun.,2020

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions;European Journal of Medicinal Chemistry;2024-11

2. SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening;SLAS Discovery;2024-09

3. A Structural Comparison of Oral SARS-CoV-2 Drug Candidate Ibuzatrelvir Complexed with the Main Protease (M^pro) of SARS-CoV-2 and MERS-CoV;JACS Au;2024-07-30

4. Assay Development and Validation for Innovative Antiviral Development Targeting the N-Terminal Autoprocessing of SARS-CoV-2 Main Protease Precursors;Viruses;2024-07-29

5. Improved synthesis of two quisqualic acid analogs containing hydantoin and imidazolidinone moieties;Chemistry of Heterocyclic Compounds;2024-06